{"id":62399,"date":"2025-09-08T11:18:32","date_gmt":"2025-09-08T05:48:32","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=62399"},"modified":"2025-09-08T11:18:32","modified_gmt":"2025-09-08T05:48:32","slug":"indias-generic-medicines-ensuring-affordable-healthcare-worldwide","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/indias-generic-medicines-ensuring-affordable-healthcare-worldwide\/","title":{"rendered":"India\u2019s Generic Medicines: Ensuring Affordable Healthcare Worldwide"},"content":{"rendered":"<h2><b>Indian Generic Medicines Latest News<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Indian pharmaceutical sector, heavily reliant on the U.S. \u2014 which accounts for over 31% of its exports and sources nearly half of its generics from India \u2014 faces serious concerns over potential U.S. sector-specific duties.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">With the global generic market projected to reach $614 billion by 2030, ongoing trade negotiations with Washington are crucial for the industry\u2019s future.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Policymakers worry that U.S. tariff threats could undermine India\u2019s role as a key global supplier of affordable medicines, raising broader questions of public interest and long-term viability.<\/span><\/li>\n<\/ul>\n<h2><b>India\u2019s Contribution to Affordable Healthcare<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India supplies about 20% of all generic drugs and is known as the \u201cpharmacy of the world.\u201d\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It produces affordable versions of brand name medicines, which are widely prescribed around the world.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Indian generics already dominate U.S. prescriptions, accounting for over 90% in areas like diabetes, anxiety, depression, and cancer.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">They saved the U.S. healthcare system $219 billion in 2022 alone, and nearly $1.3 trillion between 2013 and 2022 \u2014 underscoring India\u2019s indispensable role in global healthcare affordability.<\/span><\/li>\n<\/ul>\n<h2><b>U.S. Tariff Threats and Indian Pharma\u2019s Stakes<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The U.S., India\u2019s largest pharmaceutical export market, sources nearly half of its generics from India, making tariff threats a major concern for policymakers.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">With the global generic market projected to reach $614 billion by 2030, the <\/span><b>outcome of U.S.\u2013India trade talks is critical for the industry\u2019s future<\/b><span style=\"font-weight: 400;\"> and global access to affordable medicines.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Commentators suggest <\/span><b>India should use its pharmaceutical strength in bilateral trade negotiations, positioning Indian generics as a global public good<\/b><span style=\"font-weight: 400;\">.\u00a0<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">To do so, India must recalibrate its trade and investment strategy while mobilising public opinion in the U.S. and beyond.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3><b>Key U.S. Concerns in Negotiations<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Trump administration\u2019s main concerns are <\/span><b>high drug prices in the U.S.<\/b><span style=\"font-weight: 400;\"> and <\/span><b>India\u2019s intellectual property (IP) regime<\/b><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">It is pushing <\/span><span style=\"font-weight: 400;\">international reference pricing (IRP) to cut drug prices<\/span><span style=\"font-weight: 400;\">, while also seeking stronger IPR protections that extend monopolies for Big Pharma.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">This would <\/span><b>raise drug costs<\/b><span style=\"font-weight: 400;\"> and <\/span><b>delay generic entry into global markets<\/b><span style=\"font-weight: 400;\">.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The U.S. also demands extended patent exclusivity and stricter data protection beyond TRIPS requirements, using FTAs as leverage.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">So far, India has resisted such norms and must continue safeguarding TRIPS flexibilities, including compulsory licensing provisions.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">To safeguard exports, India is prepared to make concessions, including supplying generics at 20\u201325% of branded prices for three years after patent expiry, followed by further 10\u201315% reductions over seven years.<\/span><\/li>\n<\/ul>\n<h2><b>Need for a Strategic Shift in Trade Negotiations<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India must move beyond a transactional approach in its Bilateral Trade Agreement (BTA) talks with the U.S.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Indian Pharmaceutical Alliance (IPA) had proposed reducing import tariffs on U.S. pharma products to zero, but this fell flat as U.S. concerns lie elsewhere.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Despite earlier exemptions, President Trump imposed levies of 26% plus penalties of 25% on Indian pharma imports, signalling that financial incentives alone cannot resolve issues.<\/span><\/li>\n<\/ul>\n<h3><b>India\u2019s Negotiating Capital<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India has long upheld its patent laws against foreign pressure and now holds negotiating capital to make a strategic move.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">By highlighting the <\/span><b>global public good created by Indian generics<\/b><span style=\"font-weight: 400;\">, India can strengthen its bargaining power.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Offering joint ventures in the pharma sector not just to the Global South but also to the U.S. and EU could recalibrate the trade dynamic in India\u2019s favour.<\/span><\/li>\n<\/ul>\n<h3><b>Diversification of Markets<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India must diversify pharma trade and investment beyond the U.S., tapping into growing markets in West Asia, Central Asia, Africa, South America, China, Russia, and ASEAN.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Overseas investments with social impact can build stronger global alliances and reduce dependence on U.S. markets.<\/span><\/li>\n<\/ul>\n<h3><b>Focus on Technology Transfer and R&amp;D<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India should link price reductions on generics supplied to the U.S. with demands for technology transfer, voluntary licensing, and collaborative R&amp;D.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The <\/span><b>India\u2013U.S. TRUST<\/b><span style=\"font-weight: 400;\"> (Transforming the Relationship Utilizing Strategic Technology) initiative should be directed toward biotechnology, pharma manufacturing, and innovation partnerships.<\/span><\/li>\n<\/ul>\n<h2><b>Conclusion: Championing Public Health as a Global Good<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">India must resist unreasonable U.S. demands while promoting generics as a global public good.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">By pursuing joint ventures worldwide, especially with the Global South, India can expand its role as a key supplier of affordable essential medicines.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">This strategic move would protect public health, secure domestic industry interests, and position Indian pharma as a global leader.<\/span><\/li>\n<\/ul>\n<p><b>Source:<\/b> <a href=\"https:\/\/www.thehindu.com\/business\/indian-generics-as-global-public-good\/article70015954.ece#:~:text=Affordable%20generic%20medicines%20exported%20from,USD%20between%202013%20and%202022.\" target=\"_blank\" rel=\"nofollow noopener\"><span style=\"font-weight: 400;\">TH<\/span><\/a><span style=\"font-weight: 400;\"> | <\/span><a href=\"https:\/\/inductusglobal.com\/why-does-the-world-continue-to-source-medicines-from-india\/\" target=\"_blank\" rel=\"nofollow noopener\"><span style=\"font-weight: 400;\">IG<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Indian generics dominate global prescriptions, saving billions in healthcare costs. Trade talks with the U.S. pose challenges, but India champions generics as a global public good.<\/p>\n","protected":false},"author":18,"featured_media":62411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18],"tags":[2560,60,22,59],"class_list":{"0":"post-62399","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-mains-current-affairs","8":"tag-indian-generic-medicines","9":"tag-mains-articles","10":"tag-upsc-current-affairs","11":"tag-upsc-mains-current-affairs","12":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/62399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=62399"}],"version-history":[{"count":0,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/62399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/62411"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=62399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=62399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=62399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}